Log In
Print
BCIQ
Print
Print this Print this
 

RE-021

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionSmall molecule dual angiotensin and endothelin receptor antagonist
Molecular Target Angiotensin receptor ; Endothelin receptor
Mechanism of ActionEndothelin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNephropathy
Indication DetailsTreat focal segmental glomerulosclerosis (FSGS)
Regulatory Designation

Partner

Retrophin Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today